Allogene Therapeutics (ALLO) stock surged over 50% to a two-year high after positive Phase 2 data for lymphoma drug Cema-Cel showed a 97.7% drop in cancer DNA. TD Cowen called the results a "home run," maintaining a 'Buy' rating as the treatment showed superior efficacy compared to the control group.